Speaker Profile
Ph.D., President and CEO, Caribou Bio
Biography
Dr. Haurwitz is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company’s inception in 2011. She is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Dr. Haurwitz with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Dr. Haurwitz earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Catriona Jamieson, UC San Diego
PMWC Award Ceremony
• Emmanuelle Charpentier, Max Planck (J. Craig Venter Visionary Award · Nobel Laureate)
• Jay Bradner, Amgen (Pioneer)
• Adrian Krainer, Cold Spring Harbor Laboratory (Luminary)
• Randy Schekman, UC Berkeley (Nobel Laureate, Pioneer)
Featured Speakers
• Emmanuelle Charpentier, Max Planck
• Randy Schekman, UC Berkeley
• Jay Bradner, Amgen
• Adrian Krainer, Cold Spring Harbor Laboratory
• Alexis C. Komor, UC San Diego
• Nicole Gaudelli, GV
• Rachel Haurwitz, Caribou Bio
• Gene Yeo, UC San Diego
• Timothy Yu, Boston Children's / Harvard
• Shicheng Guo, Arrowhead Pharmaceuticals
• Mark A. Kay, Stanford
• Niren Murthy, UC Berkeley
• Ben Deverman, Broad Institute
• Stanley Crooke, n-Lorem / Ionis
Programming Protein Fate
Molecular glues, degraders, and induced proximity crossing into medicines.
Genome Editing Beyond the First Wave
Base, prime, and CRISPR-enabled editing moving from correction to clinic.
RNA Editing, Splice Modulation & Programmable RNA
RNA editing, ASOs, and splice modulation with chemistry already reaching patients.
In Vivo Delivery & Vector Engineering
AAV, LNP, and next-generation vectors that decide what is treatable.
From N-of-1 to Platform
Evidence, CMC, regulation, and access for individualized genetic medicines.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
